Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $52.27 USD
Change Today +0.3065 / 0.59%
Volume 120.0
As of 5:20 PM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).

takeda pharmaceutical co ltd (TKPHF) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/5/15 - $54.62
52 Week Low
12/30/14 - $41.16
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

takeda pharmaceutical co ltd (TKPHF) Details

Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, marketing, sale, and import/export of pharmaceutical drugs worldwide. It provides products in various therapeutic areas, including cardiovascular and metabolic, respiratory and immunology, oncology, central nervous system, general medicine, vaccines, and consumer healthcare drugs and quasi-drugs. The company has strategic partnership with BioMotiv, LLC; and a collaboration agreement with Mersana Therapeutics Inc. and Queen Mary University of London. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Osaka, Japan.

31,225 Employees
Last Reported Date: 06/27/14
Founded in 1781

takeda pharmaceutical co ltd (TKPHF) Top Compensated Officers

Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: ¥387.0M
Chief Medical & Scientific Officer, Director ...
Total Annual Compensation: ¥332.0M
Managing Director of Special Missions and Dir...
Total Annual Compensation: ¥93.0M
Compensation as of Fiscal Year 2014.

takeda pharmaceutical co ltd (TKPHF) Key Developments

Takeda Pharmaceutical Revises Earnings Guidance for Year Ended March 31, 2015

Takeda Pharmaceutical warned of its first annual loss after agreeing to pay around $2.4 billion to settle lawsuits over its Actos diabetes drug, amid cancer claims. The company expects to report a net loss of JPY 145 billion for the year ended in March 31, 2015, reversing its earlier profit forecast of JPY 65 billion. The warning came after it announced the US settlement agreement, which would resolve lawsuits representing some 8,000 people who used the treatment for type 2 diabetes beginning in the late 1990s. For the last business year ended on March 31, 2015, the company also braces for an operating loss of JPY 130 billion, a turnaround from the earlier projection of JPY 170 billion in profit. The company raised its annual revenue projection for the year to JPY 1,775 billion from JPY 1,725 billion estimated in February 2015, citing a weaker yen and higher-than-expected sales of gout and other drugs. Operating loss expected to be JPY 130,000 against previous guidance of operating profit of JPY 170,000. Basic loss per share expected to be JPY 184.39 against previous guidance of basic earnings per share of JPY 82.64. Net profit will also be negatively impacted by the write-off of deferred tax assets due to the fiscal year 2015 tax reform in Japan (approximately JPY 8 billion). The latest estimate for revenue is due to stronger growth of new products such as ENTYVIO for ulcerative colitis and Crohn's disease, better resilience of COLCRYS for gout in the US, and also further weakening of the yen. All profit lines from operating profit and below are impacted by a provision recognized to cover the U.S.

Takeda Pharmaceutical and Takeda Pharmaceuticals U.S.A Agrees to Settle ACTOS Product Liability Lawsuits and Claims

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. announced that they have reached an agreement expected to resolve the vast majority of ACTOS (pioglitazone HCl) product liability lawsuits pending against Takeda in the U.S. Takeda will take a $2.7 billion charge against earnings in the fourth quarter of fiscal year 2014 to cover the settlement and the costs associated with defending remaining cases and for other related litigation. The settlement will become effective if 95% of current litigants and claimants opt into the settlement. Once that threshold is achieved, Takeda will pay $2.37 billion into a settlement fund. However, that figure will rise to $2.4 billion if 97% or more of the current litigants and claimants opt to participate in the settlement. Takeda believes that the claims made in this litigation are without merit and does not admit liability. Takeda believes the company acted responsibly with regard to ACTOS and that ACTOS has a positive benefit/risk profile for the treatment of type 2 diabetes. Takeda's decision to settle does not change the company's continued commitment to ACTOS. ACTOS continues to be available as a treatment option in the U.S., Japan and other countries. Pioglitazone has been approved for use in 95 countries, including the U.S., Japan, several in Europe, Australia, Brazil, Canada and Russia, to highlight a few. The settlement will reduce financial uncertainties for the company and provides a significant degree of assurance toward resolving a high percentage of the ACTOS product liability claims. The settlement allows the company to fully focus on developing innovative medicines for patients around the world. Under the settlement, current litigants and claimants who meet prescribed criteria would receive payouts from the fund. The settlement will not affect Takeda's ability to pay dividends.

TWi Pharmaceuticals, Inc. Announces Settlement with Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals U.S.A., Inc., Takeda Pharmaceuticals America, Inc. on Dexilant(R) Litigation

TWi Pharmaceuticals, Inc. announced that it has entered into a Settlement Agreement with Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals U.S.A., Inc., Takeda Pharmaceuticals America, Inc. to settle and dismiss all outstanding patent litigation related to TWi's generic dexlansoprazole delayed release capsules for oral administration in 30 mg and 60 mg dosage strengths. An Abbreviated New Drug Application for TWi's generic product is currently under review at the U.S. Food and Drug Administration. If approved, TWi's product would be a generic version of Takeda's Dexilant. The Settlement Agreement allows TWi to launch its generic Dexilant one-hundred eighty (180) days after the first applicant to file its ANDA launches its generic Dexilant product, or on an earlier date under certain circumstances. As part of the settlement, the parties also entered into a License and Supply Agreement allowing TWi and its affiliates to sell Dexilant in both dosage strengths as the Authorized Generic.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TKPHF:US $52.27 USD +0.3065

TKPHF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $47.00 USD +0.31
Baxter International Inc $69.94 USD +0.51
Becton Dickinson and Co $143.94 USD +1.75
Biogen Inc $386.22 USD 0.00
Merck KGaA €99.54 EUR +3.51
View Industry Companies

Industry Analysis


Industry Average

Valuation TKPHF Industry Range
Price/Earnings 64.5x
Price/Sales 2.8x
Price/Book 1.9x
Price/Cash Flow 14.1x
TEV/Sales 1.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TAKEDA PHARMACEUTICAL CO LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at